What is the 13F Pro Quality Score for WGS?

13F Pro ranks GeneDx Holdings Corp. (WGS) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View WGS's current score at https://13fpro.ai/research/WGS (free sign-up required for the full ranking).

Which hedge funds own the most WGS stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of WGS include Corvex Management, Casdin Capital,, BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/WGS as soon as new 13F filings post.

Where does 13F Pro source WGS data?

All GeneDx Holdings Corp. fundamentals and ownership data come directly from SEC EDGAR. GeneDx Holdings Corp. files with the SEC under CIK 1818331. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is WGS in?

GeneDx Holdings Corp. (WGS) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is WGS research updated on 13F Pro?

WGS's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GeneDx Holdings Corp.(WGS)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1818331 WGS stock profile & AI dashboard →

13F Pro Quality Score

38.6/100

Rank #2,003 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

90.6/100

Profitability

21.6/100

Balance Sheet

15.3/100

Earnings Quality

30.0/100

Free Cash Flow

24.9/100

Institutional Flow

51.5/100

Revenue Scale

33.8/100

Dilution Risk

20.4/100

WGS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GeneDx Holdings Corp. (WGS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores WGS at 38.6/100 on a 32-signal composite quality model, placing it at rank #2,003 of 2,879 stocks — the bottom half of the AI-ranked universe. WGS scores in the top quartile across revenue growth (90.6). Areas of concern include balance sheet strength (15.3) and profitability (21.6), which score below median versus the broader universe. Shareholder dilution risk is elevated at 20.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GeneDx Holdings Corp. reports quarterly revenue of $102.3M, net income of $-63.3M, free cash flow of $-38.9M. Top institutional holders of WGS by reported 13-F value include Corvex Management, Casdin Capital,, BlackRock,, based on the most recent SEC filings. WGS trades on the Nasdaq exchange and files with the SEC under CIK 1818331. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate WGS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GeneDx Holdings Corp. directly from SEC EDGAR. GeneDx Holdings Corp.'s 13F Pro composite quality score has ranged between 14 and 50 since 2023, currently 38.6 — an improving long-term trajectory across 19 quarterly and live scoring snapshots.

✦

Fun facts about GeneDx Holdings Corp.

Quirks, history, and lore behind WGS — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. healthcare company · listed on Nasdaq · focused on genetic testing and diagnostics · headquartered in Connecticut.
2
The Numbers
A small-cap with annual revenue in the range of a few hundred million dollars — but it processes tens of thousands of rare-disease genetic tests a year.
3
The History
The company traces its roots to a lab originally affiliated with Yale University and was later spun out and grown into a standalone clinical genomics business.
4
The Secret
Its core focus is whole exome and whole genome sequencing — reading nearly every protein-coding gene in a patient to solve the hardest diagnostic puzzles in medicine.
5
The Lore
It is one of the few labs in the world that specializes in diagnosing ultra-rare pediatric diseases that stump everyone else — the last stop before 'we don't know what's wrong with your child.'
6
The Giveaway
Its ticker is literally the abbreviation for whole genome sequencing — and its name is a mashup of 'gene' and 'diagnosis.'

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$102.3M

Net Income

Q1 2026

$-63.3M

Free Cash Flow

Q1 2026

$-38.9M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+50.8% YoY

$305.4MFY 2024

FY20 $179.3MFY21 $212.2MFY23 $202.6MFY24 $305.4M

Net Income

+70.2% YoY

$-52.3MFY 2024

FY20 $-241.3MFY21 $-245.4MFY23 $-175.8MFY24 $-52.3M

Operating Income

+87.1% YoY

$-23.2MFY 2024

FY20 $-242.0MFY21 $-446.1MFY23 $-180.6MFY24 $-23.2M

EPS (Diluted)

+73.2% YoY

$-1.94FY 2024

FY20 $-23518.00FY21 $-1.14FY23 $-7.23FY24 $-1.94

Total Assets

+0.1% YoY

$419.4MFY 2024

FY20 $444.1MFY21 $554.1MFY23 $418.8MFY24 $419.4M

Total Debt

+0.4% YoY

$57.0MFY 2024

FY20 $20.7MFY21 $11.0MFY23 $56.7MFY24 $57.0M

Op. Cash Flow

+84.2% YoY

$-28.5MFY 2024

FY20 $-93.1MFY21 $-190.4MFY23 $-180.1MFY24 $-28.5M

Metric	FY 2024	FY 2023	FY 2021	FY 2020	FY 2018
Revenue	$305.4M +50.8%	$202.6M -4.5%	$212.2M +18.3%	$179.3M	—
Net Income	$-52.3M +70.2%	$-175.8M +28.4%	$-245.4M -1.7%	$-241.3M	—
Operating Income	$-23.2M +87.1%	$-180.6M +59.5%	$-446.1M -84.4%	$-242.0M	—
EPS (Diluted)	$-1.94 +73.2%	$-7.23 -537.0%	$-1.14 +100.0%	$-23518.00	—
Total Assets	$419.4M +0.1%	$418.8M -24.4%	$554.1M +24.8%	$444.1M	—
Total Debt	$57.0M +0.4%	$56.7M +415.9%	$11.0M -47.0%	$20.7M	—
Operating Cash Flow	$-28.5M +84.2%	$-180.1M +5.4%	$-190.4M -104.5%	$-93.1M	—

AI Insight: WGS Financial Trends

Q1 2026 operating loss of $57M and debt surging to $100M mark a sharp reversal after six quarters of improvement.

• Revenue grew from $71M in Q2 2024 to $121M in Q4 2025, a 70% rise, before pulling back to $102M in Q1 2026.

• Operating income swung from -$11M in Q2 2024 to +$9M in Q4 2025, but collapsed to -$57M in Q1 2026.

• Operating cash flow improved from -$5M in Q2 2024 to +$16M in Q3 2025, then reversed sharply to -$32M in Q1 2026.

• Equity grew steadily from $194M in Q2 2024 to $308M in Q4 2025, then contracted to $254M in Q1 2026.

⚠ Total debt jumped from $57M to $100M in Q1 2026 — first meaningful leverage increase in the observed period.

⚠ Net loss of $63M in Q1 2026 dwarfs any prior quarter; source and one-time nature of charges need clarification.

⚠ Whether revenue rebounds above $117M (Q3 2025 peak) will signal if the Q1 2026 pullback is seasonal or structural.

AI Insight: WGS Ratio Trends

Q1 2026 marks a severe profitability collapse, with operating margin cratering to -56.2% and ROIC plunging to -64.9% — the worst readings in the visible history.

• Operating margin deteriorated sharply from -11.8% in Q4 2025 to -56.2% in Q1 2026, reversing any prior improvement trajectory.

• ROIC collapsed from -15.5% in Q4 2025 to -64.9% in Q1 2026, the most extreme quarterly reading in the dataset.

• D/E ratio doubled from 0.19 in Q3–Q4 2025 back to 0.39 in Q1 2026, reversing a steady deleveraging trend from Q2 2024.

• ROE swung to -99.7% in Q1 2026 versus a positive 8.9% in Q4 2024, illustrating extreme quarter-to-quarter earnings volatility.

⚠ The sudden D/E spike to 0.39 in Q1 2026 warrants scrutiny — identify whether new debt issuance or equity erosion is the driver.

⚠ Profitability has swung wildly quarter to quarter (Q4 2024 positive, Q1 2026 deeply negative); monitor whether Q1 2026 reflects a one-off charge.

⚠ TTM operating margin of -14.9% masks the severity of the Q1 2026 quarter; trailing averages may understate current operating stress.

Get alerted when WGS's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GeneDx Holdings Corp. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of WGS

Corvex Management LP
$207.3M3,228,149 sh
Casdin Capital, LLC
$193.1M3,007,164 sh
BlackRock, Inc.
$99.6M1,550,708 sh
WESTFIELD CAPITAL MANAGEMENT CO LP
$87.9M1,369,108 sh
GOLDMAN SACHS GROUP INC
$85.7M1,334,980 sh
ARK Investment Management LLC
$85.1M1,324,583 sh
VANGUARD CAPITAL MANAGEMENT LLC
$55.1M858,583 sh
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC
$49.8M775,269 sh
Zweig-DiMenna Associates LLC
$44.3M689,290 sh
CITADEL ADVISORS LLC
$41.6M647,401 sh

Fund	Value	Shares
Corvex Management LP	$207.3M	3,228,149
Casdin Capital, LLC	$193.1M	3,007,164
BlackRock, Inc.	$99.6M	1,550,708
WESTFIELD CAPITAL MANAGEMENT CO LP	$87.9M	1,369,108
GOLDMAN SACHS GROUP INC	$85.7M	1,334,980
ARK Investment Management LLC	$85.1M	1,324,583
VANGUARD CAPITAL MANAGEMENT LLC	$55.1M	858,583
WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC	$49.8M	775,269
Zweig-DiMenna Associates LLC	$44.3M	689,290
CITADEL ADVISORS LLC	$41.6M	647,401

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put WGS on your watchlist

Track score changes the day GeneDx Holdings Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is WGS a good stock to buy?

13F Pro's AI-powered analysis of GeneDx Holdings Corp. (WGS) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for WGS are available on the WGS stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own WGS?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling WGS. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GeneDx Holdings Corp.'s investment landscape.